Author

Adam Vorn Patterson

University of Auckland

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Alisha R. DabbiD· 1 shared Amir AshoorzadehiD· 1 shared Christopher P. GuiseiD· 1 shared Emily Liu· 1 shared Ian F. HermansiD· 1 shared Jeff Bruce SmailliD· 1 shared Kathryn J. FarrandiD· 1 shared Shevan SilvaiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Alisha R. DabbORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a TLR9 dependent manner

Zhe Fu, Victoria Jackson-Patel, Kathryn J. Farrand, Christopher P. Guise, Shevan Silva, Alisha R. Dabb, Xiaojing Lin, Emily Liu, Amir Ashoorzadeh, Jeff Bruce Smaill, Ian F. Hermans, Adam Vorn Patterson

This paper shows that tarloxotinib, a hypoxia-activated prodrug, reduces tumor hypoxia and enhances immune checkpoint inhibitor efficacy through TLR9-dependent mechanisms in multiple tumor models.

bioRxiv · Feb 24, 2025 · PreprintImmunology